SCHEMBL2735290

SCHEMBL2735290

COc1ccc(OC)c(NC(=O)c2nc[nH]c2C(=O)Nc2nc3ccccc3[nH]2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.59
MEN1 O00255 7/20 0.59
ALDH1A1 P00352 2/20 0.59
CYP1A2 P05177 1/20 0.59
HPGD P15428 1/20 0.59
RAB9A P51151 11/20 0.55
NPC1 O15118 10/20 0.55
PKM P14618 4/20 0.55
SMN1; SMN2 Q16637 6/20 0.55
TP53 P04637 1/20 0.55
RXFP1 Q9HBX9 2/20 0.55
MAPT P10636 3/20 0.54
LMNA P02545 1/20 0.54
HSP90AA1 P07900 2/20 0.53
PAX8 Q06710 1/20 0.53
USP2 O75604 1/20 0.52
POLB P06746 3/20 0.52
TDP1 Q9NUW8 2/20 0.52
KLF5 Q13887 1/20 0.52
KDM4E B2RXH2 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2735297 0.93 KMT2A (0.59) KMT2AMEN1ALDH1A1CYP1A2HPGD
SCHEMBL2735270 0.91 KMT2A (0.59) KMT2AMEN1ALDH1A1CYP1A2HPGD
SCHEMBL2759976 0.91 KMT2A (0.59) KMT2AMEN1ALDH1A1CYP1A2HPGD
SCHEMBL2735335 0.90 RAB9A (0.54) KMT2AMEN1ALDH1A1CYP1A2HPGD
SCHEMBL2735353 0.90 RAB9A (0.64) KMT2AMEN1ALDH1A1CYP1A2HPGD
SCHEMBL2735277 0.89 KMT2A (0.59) KMT2AMEN1ALDH1A1CYP1A2HPGD
SCHEMBL2735288 0.86 MAPT (0.64) KMT2AMEN1ALDH1A1RAB9ANPC1
SCHEMBL2735298 0.85 KMT2A (0.67) KMT2AMEN1ALDH1A1CYP1A2HPGD
SCHEMBL2735378 0.84 RAB9A (0.60) KMT2AMEN1ALDH1A1CYP1A2HPGD
SCHEMBL2735345 0.81 RAB9A (0.56) KMT2AMEN1ALDH1A1CYP1A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 KMT2A 437/4885MEN1 3504/4885ALDH1A1 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.